Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

or

Watchlist | Portfolio | Dashboard

quotes
- Price Overview
- Performance Report
charts
technicals
options
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Wall Street - shutterstock_2269106477

S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap Barchart - Thu Mar 14, 4:32AM CDT

March S&P 500 E-Mini futures (ESH24) are trending up +0.37% this morning as market participants geared up for crucial U.S. PPI and retail sales data while also awaiting quarterly results from software...

Wall Street - shutterstock_93231562

S&P Futures Tick Higher as Investors Weigh Interest Rate Outlook Barchart - Fri Sep 8, 2023

September S&P 500 futures (ESU23) are trending up +0.08% this morning after the S&P 500 and Nasdaq closed in the red on Thursday as technology stocks dropped on concerns over the outlook for Apple, while...

Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting Business Wire - Thu May 4, 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences to Participate in May Investor Conferences Business Wire - Tue May 2, 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences Reports Full Year 2022 Financial Results and Provides Corporate Updates Business Wire - Thu Mar 16, 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Tue Feb 28, 2023

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences Announces $53.6 Million Private Placement Financing Business Wire - Thu Feb 9, 2023

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference Business Wire - Wed Feb 1, 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 Business Wire - Mon Jan 9, 2023

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need,...

Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan Spotlight Growth - Fri Jan 6, 2023

Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Use your up/down arrows to move through the symbols.

Free Barchart Webinar